What Vectorious Medical Technologies does

Vectorious Medical Technologies is an Israeli medical device company founded in 2011 and headquartered in Tel Aviv, developing the V-LAP System, a wireless implantable sensor platform for continuous left atrial pressure (LAP) monitoring in heart failure patients. The platform combines a miniature in-heart sensor with wireless power harvesting technology (eliminating the need for batteries or wires), proprietary signal processing and data mining algorithms, a mobile patient self-management application enabling twice-daily self-measurements, and cloud-based physician dashboards. The company has conducted multiple clinical trials (VECTOR-HF I, II, IIa, IIb) and accumulated 65,940+ patient-days of LAP data, described as the world's largest such dataset as of May 2026. Peer-reviewed publications have appeared in the Journal of Cardiac Failure and European Journal of Heart Failure, with conference participation at ESC, TCT, HFSA, and CSI events.

The intended business model is a traditional medical device commercial motion: physician-prescribed implant sales targeting cardiologists and heart failure specialists through hospital systems following regulatory approval, with the hardware (implant) as the primary revenue stream and ongoing monitoring platform as a recurring value layer. As of the data collection date, the V-LAP System remains an investigational device not approved for clinical use in any geography, with no disclosed pricing. In Q3 2025, Edwards Lifesciences completed a full acquisition of Vectorious for $497 million, making it a wholly-owned subsidiary within Edwards' broader cardiovascular portfolio. Prior to acquisition, the company had received EU Horizon 2020 grant funding (grant agreement No. 811765) and venture capital from Fresenius Medical Care, Broadview Ventures, GEOC, RAD BioMed Accelerator, Cleveland Clinic, Israel Innovation Authority, and Champel Capital. The company was co-founded by Eyal Orion, who serves as Chairman of the Board.

Name

Vectorious Medical Technologies

Legal name

Vectorious

Website

https://vectoriousmedtech.com

Company type

Private

Founded year

2011

Operating status

Acquired

Headcount range

101–250 employees

Short description

Vectorious Medical Technologies develops the V-LAP System, a wireless implantable left atrial pressure sensor for continuous heart failure monitoring, enabling real-time physician-guided medication adjustment. Now a subsidiary of Edwards Lifesciences following its Q3 2025 $497 million acquisition.

Ownership category

akta.pro rank

Product category

Implantable Cardiac Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB)

akta.pro secondary industries

Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Cardiology Telemedicine Platforms (HLALAGAB), Medical-Grade Device Connectivity & Device Management (MDM) (HLACAFAG)

Keywords

• Implantable cardiac sensors
• Heart failure monitoring
• Left atrial pressure
• Wireless medical devices
• Cardiac remote monitoring

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Implantable Cardiac Device Sales: Vectorious Medical Technologies is developing the V-LAP system, an implantable left atrial pressure sensor for heart failure monitoring. Following regulatory approval, the company will generate revenue through sales of the implantable device and associated monitoring platform. The technology was acquired by Edwards Lifesciences for $497 million in Q3 2025, indicating commercial development is anticipated.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Vectorious Medical Technologies develops the V-LAP System, an investigational wireless implantable sensor platform that continuously monitors Left Atrial Pressure (LAP) in heart failure patients. The system combines a miniature battery-free and wire-free sensor implanted in the heart, a mobile patient self-management application for two-minute twice-daily measurements, and cloud-based web clients for physician monitoring with real-time alerts and medication adjustment guidance. The platform is supported by the VECTOR-HF clinical program generating the world's largest LAP dataset of 65,940+ patient-days.

Product overview

Vectorious Medical Technologies offers the V-LAP System, a single unified implantable device platform designed for continuous heart failure monitoring. The platform consists of a wireless miniature sensor implanted in the heart, a companion mobile patient app for self-management and medication guidance, and cloud-based web clients for physician monitoring. The system captures the world's largest Left Atrial Pressure (LAP) dataset and uses proprietary algorithms to enable real-time medication adjustment recommendations and automatic physician alerts. The V-LAP System is currently an investigational device not approved for clinical use. Clinical validation is ongoing through the VECTOR-HF clinical study program.

Differentiator

Problem solved

Functional benefit

Products and services

• V-LAP System

Quantifiable outcome

• 65,940 days of patient LAP data - largest LAP data set in the world

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Abbott Laboratories (CardioMEMS HF System): Abbott's CardioMEMS HF System is the only commercially approved implantable wireless pulmonary artery pressure sensor for heart failure monitoring — the closest direct competitor to Vectorious's V-LAP. Both target continuous remote hemodynamic monitoring of HF patients with similar value propositions around reducing hospitalizations.
• Endotronix: Endotronix developed the Cordella PA pressure sensor system, a wireless implantable pulmonary artery pressure monitor for HF management. It is a direct competitor in the implantable remote hemodynamic monitoring category, pursuing similar use cases and clinical evidence strategy as Vectorious.

Broad incumbents

• Edwards Lifesciences: Edwards Lifesciences is Vectorious's strategic acquirer (Q3 2025, $497M) and parent company. Edwards is a global leader in structural heart, heart failure, and critical care with a commercial platform that Vectorious now plugs into; it represents the incumbent whose portfolio V-LAP complements.
• Medtronic: Medtronic is a global cardiovascular device incumbent with a broad portfolio spanning cardiac rhythm, heart failure diagnostics (e.g., LINQ ICM, TriageHF), and remote monitoring infrastructure. As a large diversified medtech, it competes broadly with the Vectorious/Edwards HF monitoring portfolio.
• Boston Scientific: Boston Scientific is a diversified cardiovascular device player with growing presence in heart failure (e.g., Cardiac Diagnostics & Services, BodyGuardian remote monitoring). It overlaps with Vectorious's HF monitoring category as part of a broader portfolio.
• BIOTRONIK: BIOTRONIK is a European cardiovascular device company offering implantable cardiac monitors (BIOMONITOR), CRM devices, and remote monitoring (Home Monitoring) services. It competes in cardiac rhythm and remote monitoring adjacent to Vectorious's HF monitoring focus.

Emerging players

• V-Wave: V-Wave developed an interatrial shunt device for heart failure with preserved ejection fraction (HFpEF). While its mechanism is different (mechanical vs. sensing), it targets the same HF patient population and represents an emerging adjunctive HF therapy that could be combined with or compete against Vectorious's monitoring approach.
• iRhythm Technologies: iRhythm's Zio long-term cardiac monitoring patch and AI-based arrhythmia detection platform competes in ambulatory cardiac monitoring and digital cardiology. It addresses a related but adjacent use case (rhythm vs. pressure) for continuous cardiac insight outside the clinic.
• AliveCor: AliveCor (KardiaMobile) provides consumer and clinical ECG-based remote cardiac monitoring. It addresses lower-acuity outpatient monitoring and represents a non-implantable, lower-cost alternative positioned upstream of Vectorious's invasive implantable solution.
• Procyrion: Procyrion is developing the Aortix percutaneous heart pump for cardiogenic shock and decompensated HF. While therapy-focused rather than monitoring, it addresses acute HF care in the same patient population Vectorious targets and represents an emerging interventional HF therapy player.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vectorious Medical Technologies